Literature DB >> 31787616

Teaming up for CAR-T cell therapy.

Ralph Wäsch1, Markus Munder2, Reinhard Marks3.   

Abstract

Mesh：

Substances：

Year:  2019        PMID： 31787616      PMCID： PMC6959173          DOI： 10.3324/haematol.2019.228676

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  18 in total

Review 1.  Are CAR T cells better than antibody or HCT therapy in B-ALL?

Authors:  Michael A Pulsipher
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 2.  Current developments in immunotherapy in the treatment of multiple myeloma.

Authors:  Martin Köhler; Christine Greil; Michael Hudecek; Sagar Lonial; Noopur Raje; Ralph Wäsch; Monika Engelhardt
Journal:  Cancer       Date:  2018-02-06       Impact factor: 6.860

Review 3.  Mechanisms of resistance to CAR T cell therapy.

Authors:  Nirali N Shah; Terry J Fry
Journal:  Nat Rev Clin Oncol       Date:  2019-06       Impact factor: 66.675

Review 4.  Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.

Authors:  Sattva S Neelapu; Sudhakar Tummala; Partow Kebriaei; William Wierda; Cristina Gutierrez; Frederick L Locke; Krishna V Komanduri; Yi Lin; Nitin Jain; Naval Daver; Jason Westin; Alison M Gulbis; Monica E Loghin; John F de Groot; Sherry Adkins; Suzanne E Davis; Katayoun Rezvani; Patrick Hwu; Elizabeth J Shpall
Journal:  Nat Rev Clin Oncol       Date:  2017-09-19       Impact factor: 66.675

Review 5.  Progress in adult ALL: incorporation of new agents to frontline treatment.

Authors:  Jessica Leonard; Wendy Stock
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 6.  Chimeric antigen receptor T-cell therapies for multiple myeloma.

Authors:  Lekha Mikkilineni; James N Kochenderfer
Journal:  Blood       Date:  2017-09-19       Impact factor: 22.113

7.  Current concepts in the diagnosis and management of cytokine release syndrome.

Authors:  Daniel W Lee; Rebecca Gardner; David L Porter; Chrystal U Louis; Nabil Ahmed; Michael Jensen; Stephan A Grupp; Crystal L Mackall
Journal:  Blood       Date:  2014-05-29       Impact factor: 22.113

8.  Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.

Authors:  Shannon L Maude; Theodore W Laetsch; Jochen Buechner; Susana Rives; Michael Boyer; Henrique Bittencourt; Peter Bader; Michael R Verneris; Heather E Stefanski; Gary D Myers; Muna Qayed; Barbara De Moerloose; Hidefumi Hiramatsu; Krysta Schlis; Kara L Davis; Paul L Martin; Eneida R Nemecek; Gregory A Yanik; Christina Peters; Andre Baruchel; Nicolas Boissel; Francoise Mechinaud; Adriana Balduzzi; Joerg Krueger; Carl H June; Bruce L Levine; Patricia Wood; Tetiana Taran; Mimi Leung; Karen T Mueller; Yiyun Zhang; Kapildeb Sen; David Lebwohl; Michael A Pulsipher; Stephan A Grupp
Journal:  N Engl J Med       Date:  2018-02-01       Impact factor: 91.245

9.  Severe Cytokine-Release Syndrome after T Cell-Replete Peripheral Blood Haploidentical Donor Transplantation Is Associated with Poor Survival and Anti-IL-6 Therapy Is Safe and Well Tolerated.

Authors:  Ramzi Abboud; Jesse Keller; Michael Slade; John F DiPersio; Peter Westervelt; Michael P Rettig; Stephanie Meier; Todd A Fehniger; Camille N Abboud; Geoffrey L Uy; Ravi Vij; Kathryn M Trinkaus; Mark A Schroeder; Rizwan Romee
Journal:  Biol Blood Marrow Transplant       Date:  2016-06-16       Impact factor: 5.742

10.  Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life.

Authors:  Christine Greil; Monika Engelhardt; Gabriele Ihorst; Katja Schoeller; Hartmut Bertz; Reinhard Marks; Robert Zeiser; Justus Duyster; Hermann Einsele; Jürgen Finke; Ralph Wäsch
Journal:  Haematologica       Date:  2018-09-20       Impact factor: 9.941
View more
  2 in total

Review 1.  Allogeneic Stem Cell Transplantation in Multiple Myeloma.

Authors:  Christine Greil; Monika Engelhardt; Jürgen Finke; Ralph Wäsch
Journal:  Cancers (Basel)       Date:  2021-12-23       Impact factor: 6.639

Review 2.  Adverse Renal Effects of Anticancer Immunotherapy: A Review.

Authors:  Maciej Borówka; Stanisław Łącki-Zynzeling; Michał Nicze; Sylwia Kozak; Jerzy Chudek
Journal:  Cancers (Basel)       Date:  2022-08-23       Impact factor: 6.575
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.